Categories | Survivors (n = 75) | Non-survivors (n = 43) | p value |
---|---|---|---|
Age (yr) | 59.3 ± 15.3 | 67.6 ± 14.1 | 0.004 |
Sex (male, %) | 47 (62.6%) | 29 (67.4%) | 0.590 |
APACHE II | 18 (14, 22) | 26 (19, 30) | < 0.001 |
SOFA | 12 (10, 13) | 14 (12, 16) | < 0.001 |
Diagnosis (n, %) | |||
 Pneumonia | 15 (20.0%) | 13 (30.2%) | 0.208 |
 Abdominal infection | 38 (50.7%) | 17 (39.5%) | 0.250 |
 Biliary tract infection | 4 (5.3%) | 2 (4.7%) | 0.863 |
 CRBSI | 4 (5.3%) | 2 (4.7%) | 0.863 |
 Cellulitis | 10 (13.3%) | 5 (11.6%) | 0.802 |
 Others* | 4 (5.3%) | 4 (9.3%) | 0.405 |
Comorbidities | |||
 HTN | 36 (48.0%) | 25 (58.1%) | 0.284 |
 DM | 28 (37.3%) | 22 (51.2%) | 0.143 |
 CAD | 14 (18.7%) | 13 (30.2%) | 0.147 |
 CKD | 5 (6.7%) | 6 (14.0%) | 0.194 |
 COPD | 7 (9.3%) | 8 (18.6%) | 0.151 |
 Timing of echo (hr from admission) | 12 (8,18) | 13 (9, 16) | 0.905 |
 Maximum NE dose (μg/kg/min) | 0.36 (0.18, 0.75) | 0.81 (0.40, 1.61) | 0.001 |
 Fluid administered (ml) | 2560 (1366, 3140) | 2880 (1629, 3530) | 0.766 |
 Lactate (mmol/L) | 3.5 (2.7, 4.2) | 4.0 (3.3, 4.9) | 0.185 |
 MV duration (hr) | 108 (67, 240) | 203 (105, 340) | 0.051 |
 ICU length of stay (day) | 7 (4, 12) | 10 (6, 15) | 0.233 |